← Monday 2 Novembernote 5 of 13
Health researchMon 2 Nov 2026 · 5 of 13

Imaging biomarker predicts breast cancer response to AKT inhibitors

Verified · 5/5 supported1 cited · 1 min read

Medical Xpress reports that researchers at The Hong Kong Polytechnic University have developed an imaging biomarker called the Tumour Heterogeneity Index (THI) to noninvasively assess breast cancer patients' response to AKT inhibitors before treatment . Medical Xpress reports that patients with a high THI achieved an estimated pathological complete response (pCR) rate of 56.1%, significantly higher than those with a low THI . Medical Xpress reports that the THI technology could help patients receive the most appropriate treatment at an earlier stage . Medical Xpress reports that the approach may reduce unnecessary side effects and enable clinicians to better tailor treatment strategies to individual patients .

Why it matters. Medical Xpress reports that earlier, more suitable therapy could reduce unnecessary side effects and allow clinicians to personalize treatment for breast cancer patients .

Earlier on Health research

Sun 1 Nov 2026Blocking TET2 May Reverse Radiation-Induced Immune Suppression in CancerMedical Xpress reports that researchers at the University of Chicago identified a mechanism to make immune cells reprogrammed by radiation therapy attack tumors rather than protect them. Medical Xpress reports that radiation activates the protein TET2 on bone‑marrow immune cells, removing chemical tags from RNA and locking them into an immune‑suppressing state. Medical Xpress reports that blocking TET2 causes these immune cells to fight cancer, enhancing the effectiveness of radiation and immunotherapy to shrink tumors and control metastasis. Medical Xpress reports that radiation therapy is administered to 50%–60% of cancer patients and kills tumor cells by damaging DNA. Medical Xpress reports that radiation can trigger the expansion of myeloid‑derived suppressor cells (MDSCs), which travel to tumors and block CD8⁺ T cells, the primary tumor‑killing immune cells.Sat 31 Oct 2026FDA grants accelerated approval for first plasmid DNA immunotherapy, Voceryq, for adult RRPThe U.S. Food and Drug Administration granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid‑gxfd) to treat adults with recurrent respiratory papillomatosis (RRP). Voceryq is the first plasmid DNA‑based immunotherapy approved in the United States. RRP is a rare disease caused by human papillomavirus that produces wart‑like growths in the airways. Clinical data showed Voceryq reduces the burden of surgical intervention for RRP patients.Fri 30 Oct 2026Study Finds Fruit and Veggie Scraps Are Rich in Dietary FiberMedical Xpress reports that most people routinely discard the peels, skins, stalks and seeds of fruits and vegetables at mealtime. Medical Xpress reports that new research from King's College London suggests these discarded parts could be a valuable source of dietary fiber, offering potential health and environmental benefits. Medical Xpress reports that the study, published in the International Journal of Food Sciences and Nutrition, analyzed 12 common types of fresh produce in the U.K.. Medical Xpress reports that in 10 out of 12 cases, the 'root-to-tip' components such as peels, skins and stalks contained significantly higher levels of dietary fiber than the portions normally eaten. Medical Xpress reports that only 4% of British adults meet the recommended minimum daily intake of 30 g of dietary fiber, highlighting a public health shortfall alongside a food‑waste crisis.
Next · Health researchSingle Blood Protein Identified as Top Marker for Fatty Liver Disease →